Last reviewed · How we verify
midazolam + pethidine
Midazolam and pethidine together provide sedation and analgesia by acting as a benzodiazepine and opioid, respectively, enhancing CNS depression for procedural or acute pain management.
Midazolam and pethidine together provide sedation and analgesia by acting as a benzodiazepine and opioid, respectively, enhancing CNS depression for procedural or acute pain management. Used for Procedural sedation and analgesia, Acute pain management with sedation.
At a glance
| Generic name | midazolam + pethidine |
|---|---|
| Sponsor | Erasme University Hospital |
| Drug class | Benzodiazepine + Opioid combination |
| Target | GABA-A receptor (midazolam); mu opioid receptor (pethidine) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Sedation, Pain Management |
| Phase | FDA-approved |
Mechanism of action
Midazolam is a short-acting benzodiazepine that potentiates GABA-A receptor signaling to produce sedation, anxiolysis, and amnesia. Pethidine (meperidine) is a synthetic opioid that binds mu opioid receptors to produce analgesia and additional sedation. The combination is used clinically to achieve balanced sedation and pain relief, particularly in procedural settings.
Approved indications
- Procedural sedation and analgesia
- Acute pain management with sedation
Common side effects
- Respiratory depression
- Hypotension
- Oversedation
- Nausea and vomiting
- Dizziness
Key clinical trials
- Jejunal Ketogenesis and Type 2 Diabetes (NA)
- Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography. (PHASE2)
- Balanced Analgosedation in Bronchoscopy: Propofol/Pethidine Versus Midazolam/Pethidine (PHASE4)
- A Comparison of Oral Sedation-related Events of Three Multiagent Oral Sedation Regimens in Pediatric Dental Patients (PHASE3)
- Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures (PHASE4)
- Comparing Pediatric Dental Oral Sedation Outcomes With and Without Meperidine in Children Aged 3-7 Years (PHASE4)
- Comparison of LCBDE vs ERCP + LC for Choledocholithiasis (NA)
- The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |